A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: From APA to NICE guidelines

International Clinical Psychopharmacology

Volumn 25, Issue 6, 2010, Pages 349-355

  Pascual, Juan C ^a   Martín Blanco, Ana ^a   Soler, Joaquim ^a   Ferrer, Alicia ^a   Tiana, Thais ^a   Alvarez, Enrique ^a   Pérez, Víctor ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

borderline personality disorder; pharmacotherapy; polypharmacy

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; MOOD STABILIZER; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BORDERLINE STATE; CLINICAL PRACTICE; COMORBIDITY; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OUTCOME ASSESSMENT; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SOCIAL STATUS;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; OUTPATIENT CLINICS, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SPAIN; YOUNG ADULT;

EID: 77958490203     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32833e23ed     Document Type: Article

References (25)

1. American Psychiatric Association (APA) (2000). Diagnostic and statistical manual of mental disorders. 4th ed. revised ed. Washington, DC: American Psychiatric Association.
2. American Psychiatric Association (APA) (2001). Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 158 (Suppl 10):1-52.
3. Barrachina J, Soler J, Campins MJ, Tejero A, Pascual JC, Alvarez E, et al. (2004). Validation of a Spanish version of the diagnostic interview for bordelines-revised (DIB-R). Actas Esp Psiquiatr 32:293-298.
4. Bender DS, Skodol AE, Sanislow CA, Dyck IR, McGlashan TH, Shea MT, et al. (2001). Treatment utilization by patients with personality disorders. Am J Psychiatry 158:295-302.
5. Coccaro EF, Kavoussi RJ (1997). Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 54:1081-1088.
6. Gómez-Beneyto M, Villar M, Renovell M, Pérez F, Hernández M, Leal C, et al. (1994). The diagnosis of personality disorder with a modified version of the SCID-II in a Spanish clinical sample. J Pers Disord 8:104-110.
7. Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden HJ (2010). Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry 71:14-25.
8. Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM (2010). Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 196:4-12.
9. Loew TH, Nikel MK, Muehlbacher M, Kaplan P, Nickel C, Kettler C, et al. (2006). Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 26:61-66. (Pubitemid 43167093)
10. Markowitz P (1995). Pharmacotherapy of impulsivity, aggression and related disorders. In: Hollander E, Stein DJ, editors. Impulsivity and aggression. New York, NY: John Wiley & Sons.
11. National Institute for Clinical Excellence (NICE) (2004a). Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: NICE.
12. National Institute for Clinical Excellence (NICE) (2004b). Eating disorders: Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. Clinical Guideline 9. London: NICE.
13. National Institute for Clinical Excellence (NICE) (2009). Borderline personality disorder: treatment and management. Clinical Guideline. London: NICE.
14. Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, et al. (2004). Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 65:1515-1519.
15. Nickel MK, Nickel C, Kaplan P, Lahmann C, Muhlbacher M, Tritt K, et al. (2005). Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 57:495-499.
16. Pascual JC, Córcoles D, Castaño J, Ginés JM, Gurrea A, Martín-Santos R, et al. (2007). Hospitalization and pharmacotherapy for borderline personality disorder in a psychiatric emergency service. Psychiatr Serv 58:1199-1204.
17. Rinne T, Ingenhoven T (2007). Pharmacotherapy of severe personality disorders: a critical review. In: van Luyn B, Akhtar S, Livesley WJ, editors. Severe personality disorders, major issues in everyday practice. New York, Cambridge, Melbourne: The Cambridge Press.
18. Rinne T, Van den Brink W, Wouters L, Van Dyck R (2002). SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 159:2048-2054.
19. Salzmann C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, et al. (1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 15:23-25.
20. Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J, et al. (2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 65:379-385.
21. Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, et al. (2005). Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 162:1221-1224.
22. Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, et al. (2005). Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 19:287-291.
23. Tyrer P, Bateman AW (2004). Drug treatment for personality disorders. Adv Psych Treatment 10:389-398.
24. Zanarini MC, Frankenburg FR, Hennen J, Silk KR (2004a). Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry 65:28-36.
25. Zanarini MC, Frankenburg FR, Parachini EA (2004b). A preliminary, randomized trial of fluoxetine, olanzapine, an olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 65:903-907.